Interpace Biosciences, Inc.
IDXG
$0.9077
-$0.0823-8.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.55% | 19.27% | 16.98% | 16.62% | 10.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.55% | 19.27% | 16.98% | 16.62% | 10.78% |
| Cost of Revenue | 8.28% | 10.47% | 8.75% | 1.45% | 1.53% |
| Gross Profit | 10.28% | 24.46% | 21.89% | 26.93% | 16.86% |
| SG&A Expenses | 13.66% | 8.21% | 7.90% | 3.58% | -2.35% |
| Depreciation & Amortization | -- | -- | -- | -97.66% | -82.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.85% | 7.63% | 5.64% | -0.36% | -3.57% |
| Operating Income | 2.19% | 114.40% | 120.11% | 397.43% | 613.69% |
| Income Before Tax | 14.52% | 219.98% | 231.65% | 710.16% | 360.58% |
| Income Tax Expenses | -17.65% | 5.88% | -76.47% | 0.00% | 750.00% |
| Earnings from Continuing Operations | 14.64% | 221.35% | 233.97% | 699.28% | 359.37% |
| Earnings from Discontinued Operations | -48.15% | 26.27% | 21.29% | 65.87% | 98.59% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.25% | 257.25% | 274.46% | 491.46% | 129.99% |
| EBIT | 2.19% | 114.40% | 120.11% | 397.43% | 613.69% |
| EBITDA | 1.24% | 90.89% | 80.86% | 185.62% | 157.89% |
| EPS Basic | 2.10% | 233.15% | 245.91% | 483.56% | 129.17% |
| Normalized Basic EPS | 13.21% | 215.12% | 225.81% | 748.81% | 365.84% |
| EPS Diluted | -75.88% | 79.57% | 135.45% | 479.98% | 128.97% |
| Normalized Diluted EPS | -71.63% | 63.37% | 112.88% | 745.96% | 364.72% |
| Average Basic Shares Outstanding | 1.42% | 1.53% | 1.61% | 1.53% | 1.55% |
| Average Diluted Shares Outstanding | 394.58% | 396.87% | 264.13% | 1.94% | 1.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |